Question 1

Who are the top researchers at Leo Pharma (United States)?

Accepted Answer

Ranked on the quality score, Sanjeev Balu, Karen A. Veverka and Shannon K. R. Schneider lead among researchers whose main affiliation is Leo Pharma (United States).

Question 2

What are the most cited papers from Leo Pharma (United States)?

Accepted Answer

The most cited paper from Leo Pharma (United States) is "Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial" (Andrew Blauvelt, Richard G B Langley, J.‐P. Lacour et al., 2022), with 79 citations. Next come "Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL ‐13 inhibition" (41) and "Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis" (23).

Question 3

Which research topics does Leo Pharma (United States) publish most on?

Accepted Answer

By volume in 2022-now: Dermatology and Skin Diseases, Contact Dermatitis and Allergies, Asthma and respiratory diseases and Urticaria and Related Conditions.

Question 4

Which fields of science does Leo Pharma (United States) work in?

Accepted Answer

In all years, 80% of research at Leo Pharma (United States) is in Health Sciences, 15% in Life Sciences. Its largest fields are Medicine (77%), Immunology and Microbiology (13%), Health Professions (3%). It does 2.4× the world's share of Health Sciences.

Question 5

Is Leo Pharma (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 254% higher than in 2018-2021.